In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylating Agents Should Be Implemented Prior to Transplant

In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylating Agents Should Be Implemented Prior to Transplant

By Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies FEATURING Rami Komrokji

181 views

January 28, 2020

Comments 0

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

480 views

ASH 2023 Insights: "Guadecitabine in Higher-Risk MDS and CMML Under …

Insights from 2023 ASH Annual Meeting

S. Urrutia

63 views

A Case of CMML With Recurrent Skin Involvement

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Arslan Davulcu

13 views

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not Survi…

Insights from 2023 ASH Annual Meeting

D. Tremblay

37 views

SOHO 2021 Update on CMML Overview of the Most Recent Data

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

G. Montalban-Bravo

56 views

2020 SOHO Updates on Oral HMAs in MDS: Can FDA-Approved Decitabine/C…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

G. Garcia-Manero

165 views

MD Anderson Immune Checkpoint Based Approaches in AML & MDS: Which C…

Naval Daver

148 views

2020 Update on Atypical CML, CMML & CNL: Is There Clinical Benefit t…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Tyner

41 views

How to Calculate Risk in MDS Patients?

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Sekeres

93 views

TGF Beta Pathway Inhibition in MDS: Luspatercept Significantly Decre…

University of Miami's 2nd Biennial Miami Leukemia Symposium

A. Verma

115 views